Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MeNZB Vaccine in Healthy Adults
NCT00443157Phase 2Completed
- Sponsor
- UK Health Security Agency
- Start
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NZ MenB OMV vaccine in meningococcal group B infection (MenB) (2 arms), sponsored by UK Health Security Agency. Primary endpoint: Serum Bactericidal Antibody. Started Feb 2006; status: completed.
02
Drugs
NZ MenB OMV vaccine
03
Conditions
meningococcal group B infection (MenB)
Beyond the preview
Go deeper on NCT00443157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00443157.